NCT05677308Completed
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study in Patients With BRCA Mutated HER2 Negative High Recurrent Risk Breast Cancer in the Adjuvant Setting
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 61 (actual)
- First submitted
- 9 Jan 2023
- Start date
- 7 Mar 2023
- Primary completion date
- 18 Feb 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Childhood cancers
- NCT number
- NCT05677308
What you commit to
- Study type: Observational
- Participants enrolled: 61
- From 7 Mar 2023 to the primary completion date, 18 Feb 2026
- 38 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who have no treatment history with LYNPARZA
Who the study is looking for
- The patients who started treatment with LYNPARZA for the first time for the approved indication "Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent risk breast cancer"
Sex: All · Does not accept healthy volunteers
Sites (38)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.